Brokerages Anticipate PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) to Announce -$0.67 Earnings Per Share

Wall Street analysts forecast that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will post ($0.67) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for PhaseBio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.76). PhaseBio Pharmaceuticals reported earnings of ($0.87) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 23%. The business is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that PhaseBio Pharmaceuticals will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($1.72). For the next financial year, analysts anticipate that the firm will report earnings of ($1.66) per share, with EPS estimates ranging from ($2.09) to ($1.16). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.51). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $4.92 million.

Separately, Needham & Company LLC dropped their target price on PhaseBio Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 28th.

PhaseBio Pharmaceuticals stock traded up $0.12 during trading hours on Tuesday, reaching $1.09. The stock had a trading volume of 2,612 shares, compared to its average volume of 570,204. PhaseBio Pharmaceuticals has a 52 week low of $0.96 and a 52 week high of $4.24. The business’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.96. The company has a market cap of $53.07 million, a price-to-earnings ratio of -0.35 and a beta of 1.98.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James & Associates purchased a new stake in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $40,000. IPG Investment Advisors LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the 4th quarter worth approximately $76,000. Squarepoint Ops LLC raised its position in shares of PhaseBio Pharmaceuticals by 29.8% during the 3rd quarter. Squarepoint Ops LLC now owns 27,083 shares of the company’s stock valued at $84,000 after buying an additional 6,216 shares during the period. Pura Vida Investments LLC purchased a new stake in shares of PhaseBio Pharmaceuticals during the 3rd quarter valued at approximately $87,000. Finally, Citadel Advisors LLC lifted its holdings in PhaseBio Pharmaceuticals by 169.3% in the fourth quarter. Citadel Advisors LLC now owns 37,452 shares of the company’s stock valued at $98,000 after acquiring an additional 23,545 shares during the last quarter. Hedge funds and other institutional investors own 57.43% of the company’s stock.

PhaseBio Pharmaceuticals Company Profile (Get Rating)

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.

Recommended Stories